ABCFish2: Anisakis Blastocystis Cryptosporidium Fish Serology

Sponsor
University Hospital, Lille (Other)
Overall Status
Completed
CT.gov ID
NCT02666092
Collaborator
Institut Pasteur de Lille (Other), ANSES (Other), Hôpital Cochin (Other), Région Nord-Pas de Calais, France (Other)
105
1
23
4.6

Study Details

Study Description

Brief Summary

Anisakidae frequently infect fish species that are commonly eaten by humans. Some of them are recognized as zoonotic diseases agents, and have a high impact on human health.

Infestation results from the ingestion of living larvae from contaminated fishes. It can be asymptomatic or symptomatic, resulting in acute gastric, acute intestinal or chronic forms. Allergic manifestations are frequently encountered in gastric forms, but allergic symptoms can also occur in isolation, after ingestion of Anisakidae antigens contained in raw or cooked fish, and may masquerade as fish allergy.

In this study, we aim to characterize the relationship between Anisakidae and/or fish sensitization and the presence of allergic manifestations in patients recruited in the general population and presenting fish allergy resulting from ingestion, cutaneous or respiratory contact. We will also determine the respective role of Anisakidae or fish sensitization in patients with fish allergy. Then, we will determine the prevalence of previous Anisakidae infections among these patients and a matched control population. We will also compare the performances of serological tests (ImmunoCAP, immunoelectrophoresis and Western Blot) for the diagnosis of Anisakidae allergy or infection. Lastly, we will explore the relationship between domestic exposure to Anisakidae or fish antigens and the occurrence of associated pathologies (Anisakidae or fish allergy/sensitization; Anisakidae infection).

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaire
  • Biological: Detection of anti-Anisakis and anti-fish antibodies

Detailed Description

First, 51 patients with fish allergy will be recruited from the Parasitology-Mycology and Immunology Laboratories of Lille University Hospital databases (serology for anti-Anisakis or anti-fish detection). Then, clinical (characteristics of allergic manifestations) and epidemiological (domestic exposure to fish) data will be collected, and anti-fish or Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), or ImmunoCAP, immunoelectrophoresis, Western Blot, respectively. Similar serological tests will be performed for a control group of 51 matched subjects who will be recruited among Lille University Hospital workers.

Study Design

Study Type:
Observational
Actual Enrollment :
105 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Protists and Nematodes Fish Parasites: From Their Circulation in Ecosystems to Their Impact on Human Health - Role of Anisakidae and/or Fish Flesh Antigens in Fish Allergies.
Study Start Date :
Feb 1, 2015
Actual Primary Completion Date :
Jan 1, 2017
Actual Study Completion Date :
Jan 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Fish allergy

51 subjects presenting allergic manifestations after digestive, cutaneous, or respiratory contact with fish will be recruited. Interventions will include: A questionnaire on domestic exposure to fish, and on the characteristics of clinical manifestations A detection of anti-Anisakis and anti-fish antibodies

Other: Questionnaire
Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)

Biological: Detection of anti-Anisakis and anti-fish antibodies
Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.

Control

51 subjects presenting no allergic manifestations after contact with fish. Interventions will include: A questionnaire on domestic exposure to fish A detection of anti-Anisakis and anti-fish antibodies

Other: Questionnaire
Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)

Biological: Detection of anti-Anisakis and anti-fish antibodies
Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.

Outcome Measures

Primary Outcome Measures

  1. the frequency of anti-Anisakis and/or anti-fish IgE by serum analysis [contact by phone during 30 min at only visit (inclusion)]

    comparison between subjects with fish allergy and a matched control population, presenting no fish allergy.

Secondary Outcome Measures

  1. anti-Anisakis and/or anti-fish IgE level by serum analysis [contact by phone during 30 min at only visit (inclusion)]

    Comparison between subjects with fish allergy and a matched control population, presenting no fish allergy.

  2. the frequency of anti-Anisakis and anti-fish IgE in patients with fish allergy by serum analysis [contact by phone during 30 min at only visit (inclusion)]

  3. nomber of subjects of previous Anisakidae infections [contact by phone during 30 min at only visit (inclusion)]

    questionnaire-based diagnosis, supported by serological testing between patients with fish allergy and a matched control population, presenting no fish allergy.

  4. Measure of the performances of serological tests [at work medical visit (inclusion)]

    Comparison of the performances of serological tests (ImmunoCAP, immunoelectrophoresis and Western Blot) for the diagnosis of Anisakidae allergy or infection.

  5. The frequency of domestic exposure to fish parasites antigens by questionnaire [contact by phone during 30 min at only visit (inclusion)]

    It will be compared between Anisakis or fish allergic/sensitized subjects and non-allergic/non sensitized subjects. It will be compared between patients with or without previous Anisakidosis. Fish exposure will be determined taking into account the handled fish species and the local prevalences of fish parasites.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
ALLERGIC PATIENTS:
  • Previous serological assessment for anti-Anisakis or anti-fish antibodies detection (ImmunoCap and/or immunoelectrophoresis) in Lille University Hospital Center, and volume of serum conserved ≥500 µl

  • Allergic manifestations after contact with fish (asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, eosinophilic gastroenteritis, gingivostomatitis, angioedema, bronchospasm, anaphylaxis)

CONTROL SUBJECTS:
  • Serological assessment for infectious disease during a routine occupational health consultation in Lille University Hospital Center

  • Absence of fish allergy

Exclusion Criteria:
  • Pregnant or breast-feeding female

  • Patient with no social insurance

  • Patient unwilling to comply with the protocol

  • Patient unable to understand the study and its objectives

  • Patient under guardianship

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHRU Lille France

Sponsors and Collaborators

  • University Hospital, Lille
  • Institut Pasteur de Lille
  • ANSES
  • Hôpital Cochin
  • Région Nord-Pas de Calais, France

Investigators

  • Principal Investigator: Emmanuel DUTOIT, MD, University Hospital, Lille

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Lille
ClinicalTrials.gov Identifier:
NCT02666092
Other Study ID Numbers:
  • 2013_43
  • 2014-A00855-42
First Posted:
Jan 28, 2016
Last Update Posted:
Jan 18, 2017
Last Verified:
Jan 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by University Hospital, Lille
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 18, 2017